Clinical trial
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic…
NCT00460694 · Singapore General Hospital, Other · Completed
Key facts
| NCT number | NCT00460694 |
|---|---|
| Title | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies |
| Official title | A Phase II Trial on Allogeneic Cytokine-induced Killer Cell Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies |
| Acronym | alloCIK |
| Lead sponsor | Singapore General Hospital, Other |
| Collaborators | National Medical Research Council (NMRC), Singapore |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Non Hodgkin's Lymphoma, Hodgkin's Disease, Myelodysplastic Syndrome, Multiple Myeloma |
| Intervention type | Biological |
| Interventions | infusion of allogeneic CIK cells |
| Enrollment | 24 |
| Start date | Aug 1, 2006 |
| Primary completion | Dec 1, 2012 |
| Completion | Dec 1, 2012 |
| First posted | Apr 16, 2007 |
| Last update posted | Feb 10, 2017 |
| Countries | Singapore |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: